Company Overview
Tau Therapeutics, LLC (“Tau”) is a development stage biopharmaceutical company built on a revolutionary discovery of inhibiting the growth of cancer cells. Tau was formed to address the growing need for a new and different way of treating cancer. The company is focused on the research, development, repositioning and commercialization of calcium T-channel therapy agents as cytostatic anti-cancer drugs and is the world leader in developing calcium T-channel blockers for oncology and other indications.
Tau’s technology is centered on modulating the calcium ion dependent mechanisms critical to cell proliferation. Tau has applied for and been granted patent protection on this unique target, on diagnostic testing utilizing the target gene or protein, and on several chemical classes that inhibit the target in order to offer patients a personalized approach to treating cancer.